Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.
Saved in:
| Title: | Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL. |
|---|---|
| Authors: | Arseni L; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Sigismondo G; Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany.; Heidelberg University, Medical Faculty, Heidelberg, Germany., Yazdanparast H; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Hermansen JU; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K. G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Mack N; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Ohl S; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Kalter V; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Iskar M; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Kalxdorf M; Cellzome, a GSK Company, Heidelberg, Germany., Friedel D; Division of Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Rettel M; EMBL, Proteomics Core Facility, Heidelberg, Germany., Paul Y; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Ringshausen I; Department of Haematology, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom., Eldering E; Department of Experimental Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Dubois J; Department of Hematology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Kater AP; Department of Hematology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Zapatka M; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Roessner PM; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Tausch E; Division of CLL, Department of Internal Medicine III, Ulm University, Ulm, Germany., Stilgenbauer S; Division of CLL, Department of Internal Medicine III, Ulm University, Ulm, Germany., Dietrich S; Heidelberg University, Department of Hematology, Heidelberg, Germany.; Düsseldorf University, Department of Hematology, Düsseldorf, Germany., Savitski MM; EMBL, Proteomics Core Facility, Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany., Skånland SS; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K. G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Krijgsveld J; Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany.; Heidelberg University, Medical Faculty, Heidelberg, Germany., Lichter P; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Seiffert M; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.seiffert@dkfz.de. |
| Source: | Nature communications [Nat Commun] 2025 Jan 26; Vol. 16 (1), pp. 1041. Date of Electronic Publication: 2025 Jan 26. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-56318-7 |
